HQL vs. GSBD, CET, MFIC, NMFC, BCSF, MUC, BBDC, PFLT, AWF, and HQH
Should you be buying Abrdn Life Sciences Investors stock or one of its competitors? The main competitors of Abrdn Life Sciences Investors include Goldman Sachs BDC (GSBD), Central Securities (CET), MidCap Financial Investment (MFIC), New Mountain Finance (NMFC), Bain Capital Specialty Finance (BCSF), BlackRock MuniHoldings California Quality Fund (MUC), Barings BDC (BBDC), PennantPark Floating Rate Capital (PFLT), AllianceBernstein Global High Income Fund (AWF), and Abrdn Healthcare Investors (HQH). These companies are all part of the "financial services" industry.
Abrdn Life Sciences Investors vs.
Goldman Sachs BDC (NYSE:GSBD) and Abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
In the previous week, Abrdn Life Sciences Investors had 3 more articles in the media than Goldman Sachs BDC. MarketBeat recorded 4 mentions for Abrdn Life Sciences Investors and 1 mentions for Goldman Sachs BDC. Abrdn Life Sciences Investors' average media sentiment score of 1.52 beat Goldman Sachs BDC's score of 1.31 indicating that Abrdn Life Sciences Investors is being referred to more favorably in the news media.
Goldman Sachs BDC currently has a consensus price target of $13.00, indicating a potential upside of 11.64%. Given Goldman Sachs BDC's stronger consensus rating and higher probable upside, equities research analysts clearly believe Goldman Sachs BDC is more favorable than Abrdn Life Sciences Investors.
Goldman Sachs BDC received 179 more outperform votes than Abrdn Life Sciences Investors when rated by MarketBeat users. However, 68.35% of users gave Abrdn Life Sciences Investors an outperform vote while only 55.35% of users gave Goldman Sachs BDC an outperform vote.
Goldman Sachs BDC pays an annual dividend of $1.28 per share and has a dividend yield of 11.0%. Abrdn Life Sciences Investors pays an annual dividend of $1.47 per share and has a dividend yield of 11.6%. Goldman Sachs BDC pays out 224.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Goldman Sachs BDC has higher earnings, but lower revenue than Abrdn Life Sciences Investors.
Goldman Sachs BDC has a net margin of 17.01% compared to Abrdn Life Sciences Investors' net margin of 0.00%. Goldman Sachs BDC's return on equity of 15.72% beat Abrdn Life Sciences Investors' return on equity.
Goldman Sachs BDC has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Abrdn Life Sciences Investors has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.
28.7% of Goldman Sachs BDC shares are held by institutional investors. Comparatively, 32.2% of Abrdn Life Sciences Investors shares are held by institutional investors. 0.1% of Goldman Sachs BDC shares are held by company insiders. Comparatively, 10.1% of Abrdn Life Sciences Investors shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Goldman Sachs BDC and Abrdn Life Sciences Investors tied by winning 8 of the 16 factors compared between the two stocks.
Get Abrdn Life Sciences Investors News Delivered to You Automatically
Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abrdn Life Sciences Investors Competitors List
Related Companies and Tools
This page (NYSE:HQL) was last updated on 3/31/2025 by MarketBeat.com Staff
